Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ryan Bruce Corcoran, M.D.

Co-Author

This page shows the publications co-authored by Ryan Corcoran and Anthony Iafrate.
Connection Strength

1.879
  1. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
    View in: PubMed
    Score: 0.214
  2. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949.
    View in: PubMed
    Score: 0.212
  3. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421.
    View in: PubMed
    Score: 0.208
  4. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427.
    View in: PubMed
    Score: 0.187
  5. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016 Feb; 6(2):147-153.
    View in: PubMed
    Score: 0.161
  6. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 12; 5(12):1271-81.
    View in: PubMed
    Score: 0.159
  7. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr; 5(4):358-67.
    View in: PubMed
    Score: 0.152
  8. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010 Nov 23; 3(149):ra84.
    View in: PubMed
    Score: 0.113
  9. Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. Clin Cancer Res. 2022 02 15; 28(4):719-727.
    View in: PubMed
    Score: 0.062
  10. Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. Cancer. 2022 Feb 09.
    View in: PubMed
    Score: 0.062
  11. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262.
    View in: PubMed
    Score: 0.056
  12. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700.
    View in: PubMed
    Score: 0.056
  13. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079.
    View in: PubMed
    Score: 0.051
  14. Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist. 2019 02; 24(2):193-201.
    View in: PubMed
    Score: 0.049
  15. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.048
  16. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 May 17.
    View in: PubMed
    Score: 0.048
  17. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.